Mylan’s double whammy: It’s getting hurt by both fast FDA approvals and too-slow ones | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 9 August, 2017 by The TZ Newswire Staff

Mylan’s double whammy: It’s getting hurt by both fast FDA approvals and too-slow ones

The company pushed major product launches, including those of two highly-anticipated generic drugs, into its 2018 financial guidance.
read more

See also
- Next Article Are Stock Market Drawdowns During Recessions Inevitable?
- Previous Article LIVE Q&A with TopstepTrader Executives
Editorial Calender

August 2017

M T W T F S S

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

« Jul Sep »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar